Bayer Joins Forces with Evotec to Revolutionize Precision Cardiology

• Bayer and Evotec have updated their strategic collaboration to focus on developing precision treatments for cardiovascular diseases (CVDs).
• The collaboration aims to identify and validate novel targets for CVD treatments, leveraging Evotec's disease modelling capabilities using human induced pluripotent stem cells (iPSCs).
• Both companies will contribute drug targets and a comprehensive set of high-quality technology platforms for the development of innovative treatment options.
• Bayer and Evotec will share responsibilities during the pre-clinical development of potential clinical candidates, with Bayer being responsible for any subsequent clinical development and commercialisation.
• The goal of the collaboration is to build a portfolio of precision cardiology therapeutics and advance a portfolio of innovative therapies for cardiovascular diseases with high unmet medical need.
• No financial terms of the collaboration were disclosed.

The next important date, BofA Healthcare Conference, at Evotec is on 15.05.2024.

The price of Evotec at the time of the news was 9,9675EUR and was up +2,60 % compared with the previous day.
15 minutes after the article was published, the price was 9,8950EUR this corresponds to a minus of -0,73 % since publication.
At this time, the index MDAX was at 26.394,19PKT (+0,17 %).

Evotec

-4,62 %

+3,10 %

-26,88 %

-28,40 %

-50,98 %

-70,95 %

-58,56 %

+187,28 %

+293,78 %

ISIN:DE0005664809WKN:566480

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• 10J
• Max